Denmark

ResoTher Pharma is developing peptide-based drugs derived from the endogenous immunomodulator Annexin 1A as resolution therapy for diseases where neutrophil-driven inflammation plays a key pathological role. Our current focus is on cardiovascular disorders and inflammatory disorders with a large unmet medical need. The company's assets are based on the breakthrough discoveries of Professor Mauro Perretti at Barts, a pioneer in the field of Resolution of Inflammation.

Presenter: Lone Veng, CEO, ResoTher Pharma ApS